scholarly journals Prognostic Value of Androgen Receptor in Triple Negative Breast Cancer of Iranian Patients in Yazd Region

2020 ◽  
pp. 164-167
Author(s):  
Fatemeh Alsadat Nobakht ◽  
Mansour Moghimi
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Androgen Receptor ◽  
High Risk ◽  
Triple Negative Breast Cancer ◽  
Prognostic Value ◽  
Triple Negative ◽  
Tumor Location ◽  
Lymph Node Status ◽  
Ki 67

Background: Triple negative breast cancer (TNBC) is a heterogeneous disease group with a higher recurrence risk and poorer prognosis. In this study, we aimed to investigate the frequency and prognostic value of androgen receptor (AR) expression in tissues of TNBC patients.Methods: In this study a total of 60 TNBC patients treated between 2011 - 2016 in Shahid Sadoughi and Mortaz Hospital were included and their medical records were analyze. The available paraffin blocks were assessed immunohistochemically to determine AR expression. Tumors with ?10% nuclear staining were considered AR-positive, while the ones with <10% staining were considered AR-negative. The association between AR expression, and clinical-pathologic characteristics and prognosis in TNBC was analyzed. Results: The result showed that AR expression in TBNC correlated with high risk of recurrence but no significant correlation with the age, grade, tumor size, lymph node status, type of diagnosis, tumor location, and Ki-67 level was observed. Positive immunoreactivity for AR was observed in 19 out of 60 (11%) specimens. No correlation was observed between the AR expression and the age, grade, tumor size, lymph node status, type of diagnosis, tumor location, and Ki-67 level. The AR-positive patients exhibited high risk of recurrence (P=0.016) and death (P=0.015) in comparison with the AR-negative patients. Concusions: AR may not be a suitable biomarker and treatment target for the Iranian Yazd patients with TNBC.

Androgen Receptor and Enzymes in Lymph Node Metastasis and Cancer Reoccurrence in Triple-Negative Breast Cancer

2015 ◽  
Vol 30 (2) ◽  
pp. 184-189 ◽  
Author(s):  
Keely May McNamara ◽  
Tomomi Yoda ◽  
Yasuhiro Miki ◽  
Yasuhiro Nakamura ◽  
Takashi Suzuki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Androgen Receptor ◽  
Lymph Node Metastasis ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
University Hospital ◽  
Ki 67 ◽  
Node Metastasis

Background Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor, progesterone receptor and HER2. TNBCs are a diverse subgroup, but one promising marker and therapeutic target of this breast cancer is the androgen receptor (AR). Previously we demonstrated that AR and cognate intracrine pathways are associated with decreased proliferation in invasive ductal carcinoma with their decrease also detected between organ-confined and invasive diseases. Therefore, in this study, we examined the status of AR and androgen-producing enzymes during the process of metastasis to lymph nodes and cancer recurrence. Materials and Methods We studied 2 series of patients with TNBC, one from Kumamoto University Hospital composed of 16 matched cases of primary and locally or distal recurrences and the other from Tohoku University Hospital examining 46 lymph node metastasis from 23 patients. In addition to studying concordance in AR expression, we also examined the interactions between AR and Ki-67 labeling index and AR and site of distal metastasis. Results In both series, AR status was concordant between primary and recurrent/metastatic disease, but coordinated expression of AR and androgenic enzymes was lost during the process. The inverse association between AR and Ki-67, previously reported in invasive ductal carcinoma (IDC), was markedly potentiated in both lymph node and recurrent cancers. In addition, AR expression appeared to have little effect on visceral metastasis but was associated directly with bone metastasis and inversely with brain metastasis. Conclusions The results of our present study demonstrated that AR remained in the majority of metastatic samples from AR-positive primary TNBCs and that AR manipulation could be exploited in the metastatic settings of TNBC.

scholarly journals 189P The prognostic value of androgen receptor in triple negative breast cancer

2020 ◽  
Vol 31 ◽  
pp. S318
Author(s):  
D. Pratiwi ◽  
I. Purwanto ◽  
M.S. Hardianti ◽  
J. Kurnianda ◽  
K. Widayati ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Prognostic Value ◽  
Triple Negative

scholarly journals Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers

2018 ◽  
Vol 119 (1) ◽  
pp. 76-79 ◽  
Author(s):  
Séverine Guiu ◽  
Caroline Mollevi ◽  
Céline Charon-Barra ◽  
Florence Boissière ◽  
Evelyne Crapez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Prognostic Value ◽  
Triple Negative

Prognostic value of Ki-67 labeling index according to age in patients with non-metastasic triple-negative breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12118-e12118
Author(s):  
Victor Zenzola ◽  
María Antonia Cabezas-Quintario ◽  
Andrea Correa ◽  
Irene Moreno ◽  
Manuel Pedregal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Roc Curve ◽  
Prognostic Value ◽  
Triple Negative ◽  
Disease Free Survival ◽  
Time Dependent ◽  
Clinicopathologic Characteristics ◽  
Ki 67 ◽  
Poor Prognostic Factor

e12118 Background: The prognostic value of Ki67 in triple negative breast cancer (TNBC) is yet unclear because the cut-off points employed differ widely and its predictive effect may vary according to age. The purpose of this study was to analyze the role of Ki-67 among patients with TNBC, and determined the optimal Ki-67 cut-off point to demonstrate its prognostic relevance associated with patient age and treatment strategy. Methods: 201 patients treated for primary TNBC from 1999 to 2014 were identified from the breast surgery database. Clinicopathologic characteristics and outcomes were compared between patients treated with neoadjuvant or adjuvant chemotherapy. We used time-dependent receiver operating characteristic (ROC) curve and time-dependent area under the ROC curve (AUC) to evaluate the discriminative ability of Ki-67 at 3 and 5 years of follow up. A Ki-67 cut-off point was set up to maximize sensitivity and specificity. Interaction effect between age and Ki-67 on disease-free survival (DFS) and overall survival (OS) was evaluated by stratified analysis. Results: There was a non-significant Ki-67 cut off value to predict OS and DFS at 3 and 5 years neither in the whole serie (201) nor in the adjuvant group (125), and only a slightly better threshold for DFS in the neoadjuvant one (N = 46) at 5 years (AUC = 0.697). According to the coordinates of the ROC curves, the best cut-off point for Ki-67 was 60%. In the multivariate analysis (COX proportional hazards regression), high Ki-67 ( > 60%), was a poor prognostic factor for DFS in patients > 40 yo. Among the patients < 40 yo, high Ki-67 was a better prognosis factor. Conclusions: Our data suggest that a threshold of Ki-67 of 60% could provide a usefull tool to define patients with significantly different outcome in TNBC.

scholarly journals Relationship of ER, PR, HER2 / neu with Other Prognostic Factors in Breast Cancer along with the Role of Androgen Receptor in Triple Negative Breast Cancer

2021 ◽  
Vol 10 (8) ◽  
pp. 536-540
Author(s):  
Arshi Khan ◽  
Reeni Malik ◽  
Pramila Jain ◽  
Deepshikha Verma ◽  
Vedanti Newasker
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Oestrogen Receptor ◽  
Triple Negative ◽  
Receptor Expression ◽  
Proliferation Index ◽  
Lymph Node Status ◽  
Significant Information

BACKGROUND Understanding various risk factors associated with breast cancer can help in early identification & prompt treatment of patients with breast cancer. Apart from clinical parameters like age, disease presentation and menopausal status, important prognostic indicators in histopathology are size and extent of tumour, histologic type,histologic grade and lymph node status. Also, there are other factors which are not only predictive of outcome, but also direct therapies against particular molecular targets. These factors are oestrogen receptor (ER) status, progesterone receptor (PR) status, HER2 / neu status, Ki-67 proliferation index & androgen receptor (AR) status. We wanted to analyse various hormone receptors & their correlation with prognostic factors. In addition, androgen receptor expression is also studied in triple negative breast cancer cases. METHODS The study included 50 cases over a period of 18 months from January 2018 to June 2019 received in the Department of Pathology, Gandhi Medical College, Bhopal, India. These cases were subjected to histopathological & immunohistochemistry (IHC) evaluation. RESULTS Among the 50 cases studied, the most common subtype was infiltrating ductal carcinoma (NOS - no special type, 84 %). Majority of patients were ER, PR, HER2 / neu negative (48 %) and among those triple negative cases, 25 % of cases were androgen receptor positive. CONCLUSIONS Expression of the hormone receptor (ER and PR) and HER2 status may provide significant information in directing patient management. Since traditional pathological methods and IHC remain standard for guiding the use of treatment, clinicians may be challenged with equivocal results that directs towards additional testing for definitive diagnosis and, better patient outcome. The most used therapy for advanced breast cancers is based on the use of AR antagonists, such as bicalutamide and enzalutamide, first- and second-generation AR antagonists respectively. Gene signatures, bioinformatics, and other clinical trials are also beneficial for clinician in estimating the benefits expected from adjuvant chemotherapy. KEY WORDS Breast Cancer, Oestrogen Receptor, Androgen Receptor, Triple Negative

scholarly journals New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer

Oncotarget ◽  
2016 ◽  
Vol 7 (17) ◽  
pp. 24824-24831 ◽  
Author(s):  
Shuang Hao ◽  
Zhi-Xian He ◽  
Ke-Da Yu ◽  
Wen-Tao Yang ◽  
Zhi-Min Shao
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Prognostic Value ◽  
Triple Negative ◽  
Labeling Index ◽  
Ki 67
Sign in / Sign up

Export Citation Format

Share Document